News
Kazia Therapeutics Limited ("Kazia" or the "Company"), an oncology-focused biotechnology company developing innovative therapies for difficult-to-treat cancers, today announced that the first patient ...
REGENXBIO Inc. today announced new positive interim data from the Phase I/II AFFINITY DUCHENNE trial. Updates include positive functional, safety and biomarker data for RGX-202, REGENXBIO's potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback